Dimitrios G Moshovitis

P-2120. Toxicity and Adverse Outcomes of Letermovir vs. Valganciclovir Cytomegalovirus (CMV) Prophylaxis in Lung Transplantation

Dimitrios G Moshovitis, Andres E Franceschi Coll, Ahmad Nawlo, Marco Aurelio Diaz et autres

Abstract Background CMV remains a significant cause of morbidity and mortality in lung transplant (LT) recipients. While valganciclovir (vGCV) has been a mainstay of CMV prophylaxis, it is associated with treatment-limiting side effects, such as myelosuppression. Letermovir (LET), an inhibitor of the …

us (code pays fourni par la source)

An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity

Isabel H Gonzalez-Bocco, Rayven Frierson, Alyssa Cho, Fabiola A. Reyes et autres

Background: Immunocompromised individuals have a limited humoral immune response to SARS-CoV-2 vaccination and are at higher risk of severe COVID-19. Sotrovimab is a monoclonal antibody (mAb) targeting a conserved SARS-CoV-2 spike protein epitope. Methods: This phase II open-label study evaluated the safety …

us, gb (code pays fourni par la source)

Efficacy and Safety of Pemivibart Monoclonal Antibody Prophylaxis in Immunocompromised Transplant Patients: A Retrospective Cohort Study

Christine Atallah, Andres E Franceschi, Isabel H Gonzalez-Bocco, Dimitrios G Moshovitis et autres

Purpose: Immunocompromised patients, particularly solid organ transplantation (SOT) recipients, are at increased risk of severe COVID-19. Pemivibart, a monoclonal antibody targeting the class 1/4 receptor-binding domain in the SARS-CoV-2 spike protein, received emergency use authorization from the FDA for pre-exposure prophylaxis against …

us (code pays fourni par la source)

P-2170. CMV T-cell Immunity Panel (TCIP)-Guided Secondary CMV Prophylaxis Duration in Lung Transplant Recipients

M. Díaz, Hassan Alshaker, Jawad Safiia, Dimitrios G Moshovitis et autres

Abstract Background CMV infection is a complication in lung transplant recipients (LTR), with associated morbimortality. There are many antiviral regimens, but extended use can lead to toxicity. The use of a CMV-specific TCIP (CMV inSIGHT, Viracor Eurofins) is being evaluated for CMV …

us (code pays fourni par la source)

An Open-Label Phase Ii Trial of Sotrovimab (Vir-7831) Prophylaxis Against Covid-19 Infection in Immunocompromised Individuals with Impaired Sars-Cov-2 Humoral Immunity

Isabel H Gonzalez-Bocco, Rayven Frierson, Alyssa Cho, Fabiola A. Reyes et autres

us, nl (code pays fourni par la source)

Recent Advances in Diagnostic Approaches for Mucormycosis

Jawad Safiia, M. Díaz, Hassan Alshaker, Christine Atallah et autres

Mucormycosis, an invasive fungal infection caused by members of the order Mucorales, often progresses fulminantly if not recognized in a timely manner. This comprehensive review discusses the latest developments in diagnostic approaches for mucormycosis, from traditional histopathology and culture-based methods to advanced …

us (code pays fourni par la source)

2715. Toxicities and clinical consequences of valganciclovir prophylaxis in solid organ transplant recipients

Chloé Lahoud, Andres E Franceschi, Fabiola Reyes, Dimitrios G Moshovitis et autres

Abstract Background Cytomegalovirus (CMV) commonly affects solid organ transplant (SOT) recipients, with increased risks of rejection, graft failure, and other infections. While valganciclovir (vGCV) prophylaxis is effective in preventing CMV, its use is sometimes hindered by toxicity. We examined the association between …

us (code pays fourni par la source)

Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity

Isabel H Gonzalez-Bocco, Katherine Beluch, Alyssa Cho, Chloé Lahoud et autres

BACKGROUND: Multiple vaccines have been approved since August 2021 to prevent infection with SARS-CoV-2; however, 20-40% of immunocompromised people fail to develop SARS-CoV-2 spike antibodies after COVID-19 vaccination and remain at high risk of infection and more severe illness than non-immunocompromised hosts. …

us (code pays fourni par la source)

Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 Infection in Immunocompromised Individuals with Impaired SARS-CoV-2 Humoral Immunity

Isabel H Gonzalez-Bocco, Katherine Beluch, Alyssa Cho, Gillian M. Unger-Mochrie et autres

Abstract Background: Since August 2021, multiple vaccines have been approved to prevent infection with SARS-CoV-2; however, 20-40 % of immunocompromised people fail to develop SARS-CoV-2 spike antibodies after COVID-19 vaccination and remain at an exceptionally high risk of infection and more severe …

us (code pays fourni par la source)